Supemtek

RSS

Quadrivalent influenza vaccine (recombinant, prepared in cell culture)

Authorised
This medicine is authorised for use in the European Union.

Overview

Supemtek is a vaccine used to protect adults against influenza (flu).

Influenza is mainly caused by two kinds of influenza virus, known as influenza A and B. Each of these circulate as different strains and subtypes, which change over time.

Supemtek contains proteins of four different influenza A and B virus strains (type A-H1N1, type A-H3N2 and two type B strains), chosen based on the official recommendation for the annual flu season.

This EPAR was last updated on 25/11/2020

Authorisation details

Product details
Name
Supemtek
Agency product number
EMEA/H/C/005159
Active substance
  • Influenza A virus subtype H1N1 haemagglutinin, recombinant
  • Influenza A virus subtype H3N2 haemagglutinin, recombinant
  • Influenza B virus Victoria lineage haemagglutinin, recombinant
  • Influenza B virus Yamagata lineage haemagglutinin, recombinant
International non-proprietary name (INN) or common name
Quadrivalent influenza vaccine (recombinant, prepared in cell culture)
Therapeutic area (MeSH)
Influenza, Human
Anatomical therapeutic chemical (ATC) code
J07BB02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Sanofi Pasteur
Date of issue of marketing authorisation valid throughout the European Union
16/11/2020
Contact address

14 Espace Henry Vallée
69007 Lyon
France

Product information

16/11/2020 Supemtek - EMEA/H/C/005159 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Supemtek is indicated for active immunization for the prevention of influenza disease in adults.

Supemtek should be used in accordance with official recommendations.

Assessment history

How useful was this page?

Add your rating